Dodd R Y
American Red Cross, Holland Laboratory, Rockville, MD 20855, USA.
Clin Exp Immunol. 1996 May;104 Suppl 1:31-4.
Although intravenous immune globulin (IVIG) preparations may be derived from tens of thousands of donations, the residual risk of viral contamination of recovered plasma appears remarkably low, at least for human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Consequently, most pools are unlikely to contain these viruses although the situation is not as well understood for US-derived source plasma. In addition, routine preparation methods are likely to eliminate infectivity from the relatively fragile HIV. Current plasma screening measures are generally designed to maintain reasonable titres of anti-HBs in pools, perhaps contributing to the absence of HBV infection. The situation with respect to hepatitis C virus (HCV) is not well understood and it appears that sensitive screening for anti-HCV may have had an impact on the safety of at least one IVIG preparation. The implementation of effective viral inactivation procedures is expected to eliminate any further risk of HCV infection from IVIG preparations.
尽管静脉注射免疫球蛋白(IVIG)制剂可能源自数以万计的献血,但回收血浆中病毒污染的残留风险似乎非常低,至少对于人类免疫缺陷病毒(HIV)和乙型肝炎病毒(HBV)而言是这样。因此,大多数混合血浆不太可能含有这些病毒,不过对于源自美国的原料血浆,情况还不太清楚。此外,常规制备方法可能会消除相对脆弱的HIV的传染性。目前的血浆筛查措施通常旨在维持混合血浆中合理的抗-HBs滴度,这可能是导致没有HBV感染的原因之一。关于丙型肝炎病毒(HCV)的情况还不太清楚,似乎抗-HCV的敏感筛查可能对至少一种IVIG制剂的安全性产生了影响。预计实施有效的病毒灭活程序将消除IVIG制剂中HCV感染的任何进一步风险。